| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 4 | 2021 | 561 | 1.020 |
Why?
|
| Deglutition Disorders | 8 | 2020 | 297 | 0.870 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 1536 | 0.720 |
Why?
|
| Periodontal Pocket | 2 | 2012 | 15 | 0.680 |
Why?
|
| Dental Research | 2 | 2012 | 6 | 0.680 |
Why?
|
| Head and Neck Neoplasms | 7 | 2020 | 561 | 0.680 |
Why?
|
| Deglutition | 6 | 2020 | 221 | 0.670 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 597 | 0.650 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 91 | 0.650 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 475 | 0.550 |
Why?
|
| Female | 61 | 2022 | 38074 | 0.510 |
Why?
|
| Humans | 81 | 2022 | 68618 | 0.500 |
Why?
|
| Proteins | 4 | 2018 | 474 | 0.480 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 44 | 0.480 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 129 | 0.460 |
Why?
|
| Health Status Disparities | 2 | 2016 | 326 | 0.460 |
Why?
|
| Carcinogenesis | 1 | 2014 | 124 | 0.460 |
Why?
|
| Middle Aged | 37 | 2021 | 21147 | 0.450 |
Why?
|
| Male | 50 | 2022 | 37321 | 0.450 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 18 | 0.440 |
Why?
|
| Rectal Neoplasms | 3 | 2020 | 75 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 468 | 0.410 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 778 | 0.400 |
Why?
|
| Aged | 26 | 2021 | 14862 | 0.400 |
Why?
|
| Membrane Proteins | 3 | 2020 | 617 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 756 | 0.360 |
Why?
|
| South Carolina | 15 | 2019 | 2752 | 0.360 |
Why?
|
| Barium | 3 | 2020 | 52 | 0.360 |
Why?
|
| Survival Analysis | 4 | 2019 | 714 | 0.350 |
Why?
|
| Body Image | 3 | 2020 | 100 | 0.350 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 4848 | 0.340 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 508 | 0.330 |
Why?
|
| Models, Statistical | 4 | 2009 | 448 | 0.330 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 800 | 0.330 |
Why?
|
| Adult | 29 | 2020 | 21403 | 0.320 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 1851 | 0.320 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2018 | 94 | 0.320 |
Why?
|
| Prognosis | 7 | 2021 | 2093 | 0.310 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 118 | 0.300 |
Why?
|
| Deoxycytidine | 2 | 2020 | 83 | 0.300 |
Why?
|
| Risk Factors | 20 | 2020 | 5731 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 151 | 0.290 |
Why?
|
| Contrast Media | 4 | 2019 | 595 | 0.290 |
Why?
|
| Mouth Neoplasms | 3 | 2015 | 206 | 0.280 |
Why?
|
| Fluoroscopy | 5 | 2019 | 152 | 0.280 |
Why?
|
| Periodontal Attachment Loss | 1 | 2006 | 12 | 0.280 |
Why?
|
| Apoptosis | 5 | 2019 | 1641 | 0.280 |
Why?
|
| NFATC Transcription Factors | 2 | 2017 | 40 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2015 | 629 | 0.260 |
Why?
|
| Research Personnel | 1 | 2006 | 83 | 0.260 |
Why?
|
| Respiration | 2 | 2017 | 91 | 0.260 |
Why?
|
| Adolescent | 15 | 2018 | 8912 | 0.250 |
Why?
|
| Lysophospholipids | 2 | 2019 | 209 | 0.250 |
Why?
|
| Sphingosine | 2 | 2019 | 315 | 0.240 |
Why?
|
| Survival Rate | 3 | 2018 | 1056 | 0.240 |
Why?
|
| Pilot Projects | 7 | 2019 | 1342 | 0.230 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 792 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2018 | 87 | 0.230 |
Why?
|
| Polysaccharides | 3 | 2022 | 176 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 304 | 0.230 |
Why?
|
| Postoperative Complications | 3 | 2019 | 1615 | 0.230 |
Why?
|
| Video Recording | 3 | 2019 | 145 | 0.230 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 114 | 0.230 |
Why?
|
| Animals | 18 | 2022 | 20881 | 0.220 |
Why?
|
| Retrospective Studies | 16 | 2022 | 7277 | 0.220 |
Why?
|
| Software | 4 | 2009 | 418 | 0.210 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 17 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 7 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2022 | 118 | 0.210 |
Why?
|
| Logistic Models | 8 | 2010 | 1420 | 0.210 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 194 | 0.210 |
Why?
|
| Brain Injuries | 3 | 2010 | 268 | 0.210 |
Why?
|
| Young Adult | 10 | 2020 | 5717 | 0.200 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2022 | 33 | 0.200 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 4 | 2022 | 306 | 0.200 |
Why?
|
| Signal Transduction | 5 | 2019 | 2689 | 0.200 |
Why?
|
| Bayes Theorem | 4 | 2012 | 307 | 0.200 |
Why?
|
| Models, Biological | 2 | 2020 | 981 | 0.200 |
Why?
|
| Mice | 12 | 2022 | 8474 | 0.200 |
Why?
|
| Interleukin-15 | 1 | 2022 | 66 | 0.200 |
Why?
|
| Infant | 8 | 2019 | 2891 | 0.190 |
Why?
|
| Neoplasms | 3 | 2022 | 1667 | 0.190 |
Why?
|
| Pharynx | 2 | 2020 | 89 | 0.190 |
Why?
|
| Immunity | 1 | 2021 | 67 | 0.190 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2017 | 450 | 0.190 |
Why?
|
| ErbB Receptors | 2 | 2019 | 239 | 0.190 |
Why?
|
| Indazoles | 1 | 2020 | 12 | 0.190 |
Why?
|
| Age Factors | 5 | 2013 | 1864 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 28 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2018 | 132 | 0.180 |
Why?
|
| Palliative Care | 2 | 2017 | 271 | 0.180 |
Why?
|
| Barium Sulfate | 2 | 2018 | 66 | 0.180 |
Why?
|
| Adenoma | 1 | 2021 | 132 | 0.180 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 42 | 0.180 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 81 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 266 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2020 | 141 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 331 | 0.170 |
Why?
|
| Dental Hygienists | 2 | 2012 | 3 | 0.170 |
Why?
|
| Infant, Newborn | 7 | 2017 | 2455 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 23 | 0.170 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 22 | 0.170 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.170 |
Why?
|
| Fucose | 1 | 2019 | 25 | 0.170 |
Why?
|
| Amino Sugars | 1 | 2019 | 12 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2019 | 13 | 0.170 |
Why?
|
| Thioredoxins | 1 | 2019 | 26 | 0.170 |
Why?
|
| SEER Program | 2 | 2016 | 153 | 0.160 |
Why?
|
| PPAR gamma | 1 | 2019 | 95 | 0.160 |
Why?
|
| CELF1 Protein | 2 | 2015 | 7 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 111 | 0.160 |
Why?
|
| Thiazolidines | 1 | 2018 | 23 | 0.160 |
Why?
|
| Mass Spectrometry | 3 | 2008 | 284 | 0.160 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 95 | 0.160 |
Why?
|
| Heart Defects, Congenital | 2 | 2017 | 596 | 0.160 |
Why?
|
| Observer Variation | 2 | 2012 | 330 | 0.160 |
Why?
|
| Transplantation Immunology | 1 | 2018 | 11 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2020 | 3705 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 334 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 183 | 0.160 |
Why?
|
| Mouth | 1 | 2018 | 64 | 0.150 |
Why?
|
| Analysis of Variance | 4 | 2008 | 1040 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 87 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 184 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 201 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 411 | 0.150 |
Why?
|
| Frizzled Receptors | 1 | 2017 | 8 | 0.150 |
Why?
|
| Sucking Behavior | 1 | 2017 | 8 | 0.150 |
Why?
|
| Infant Behavior | 1 | 2017 | 12 | 0.150 |
Why?
|
| United States | 10 | 2018 | 7367 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 66 | 0.150 |
Why?
|
| Bottle Feeding | 1 | 2017 | 20 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 1173 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2011 | 1046 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2077 | 0.140 |
Why?
|
| Proteomics | 3 | 2015 | 246 | 0.140 |
Why?
|
| Esophagus | 1 | 2018 | 303 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2009 | 498 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 164 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 375 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 287 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 54 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2019 | 258 | 0.130 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 213 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2017 | 224 | 0.130 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 349 | 0.130 |
Why?
|
| Colostomy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 331 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2022 | 867 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 536 | 0.130 |
Why?
|
| Late Onset Disorders | 1 | 2015 | 4 | 0.130 |
Why?
|
| Ileostomy | 1 | 2015 | 14 | 0.130 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2018 | 127 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2017 | 284 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 329 | 0.120 |
Why?
|
| Trastuzumab | 1 | 2014 | 17 | 0.120 |
Why?
|
| Research Design | 2 | 2012 | 729 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 300 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2013 | 3187 | 0.120 |
Why?
|
| Speech-Language Pathology | 1 | 2014 | 24 | 0.120 |
Why?
|
| Quinazolines | 1 | 2014 | 70 | 0.120 |
Why?
|
| Quality of Life | 2 | 2020 | 1515 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 191 | 0.120 |
Why?
|
| Heart Ventricles | 2 | 2017 | 738 | 0.120 |
Why?
|
| Algorithms | 4 | 2015 | 1196 | 0.120 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 150 | 0.110 |
Why?
|
| Medication Errors | 1 | 2015 | 116 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 170 | 0.110 |
Why?
|
| Interleukin-18 | 1 | 2013 | 16 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 135 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2019 | 381 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2018 | 447 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 27 | 0.110 |
Why?
|
| RANK Ligand | 1 | 2013 | 73 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 36 | 0.110 |
Why?
|
| Oral Hygiene | 2 | 2011 | 33 | 0.110 |
Why?
|
| Cell Lineage | 1 | 2013 | 146 | 0.110 |
Why?
|
| Electrodiagnosis | 1 | 2012 | 12 | 0.110 |
Why?
|
| Spinal Cord Injuries | 2 | 2010 | 551 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 306 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 104 | 0.110 |
Why?
|
| Peroxiredoxins | 1 | 2012 | 34 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 32 | 0.110 |
Why?
|
| Autophagy | 1 | 2014 | 208 | 0.110 |
Why?
|
| Child | 6 | 2013 | 6405 | 0.110 |
Why?
|
| RNA Stability | 1 | 2013 | 55 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2013 | 132 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 3259 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2012 | 34 | 0.100 |
Why?
|
| Population Surveillance | 3 | 2009 | 285 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2013 | 305 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 332 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2019 | 2358 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2014 | 432 | 0.100 |
Why?
|
| Osteogenesis | 1 | 2013 | 152 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 848 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2012 | 35 | 0.100 |
Why?
|
| Sepsis | 1 | 2015 | 233 | 0.100 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2012 | 53 | 0.100 |
Why?
|
| Stem Cells | 1 | 2013 | 248 | 0.100 |
Why?
|
| Calibration | 1 | 2012 | 73 | 0.100 |
Why?
|
| Mice, Nude | 3 | 2019 | 294 | 0.100 |
Why?
|
| Cell Survival | 1 | 2014 | 901 | 0.100 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.100 |
Why?
|
| Biomarkers | 3 | 2013 | 1593 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 92 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2010 | 737 | 0.100 |
Why?
|
| Manometry | 1 | 2012 | 276 | 0.100 |
Why?
|
| Automobiles | 1 | 2011 | 26 | 0.100 |
Why?
|
| Acetylcysteine | 1 | 2014 | 296 | 0.100 |
Why?
|
| Housing | 1 | 2011 | 38 | 0.100 |
Why?
|
| Toothache | 1 | 2011 | 7 | 0.090 |
Why?
|
| Bias | 1 | 2012 | 148 | 0.090 |
Why?
|
| Carbonated Beverages | 1 | 2011 | 9 | 0.090 |
Why?
|
| Pre-Eclampsia | 2 | 2010 | 202 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 332 | 0.090 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 18 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 370 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 78 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 215 | 0.090 |
Why?
|
| Education, Dental | 1 | 2011 | 63 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2022 | 1200 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 74 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 232 | 0.090 |
Why?
|
| Prevalence | 4 | 2020 | 1619 | 0.090 |
Why?
|
| Dental Caries | 1 | 2011 | 40 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 1085 | 0.090 |
Why?
|
| Healthy Volunteers | 2 | 2022 | 78 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2010 | 23 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2010 | 37 | 0.090 |
Why?
|
| Smoking | 1 | 2018 | 1452 | 0.090 |
Why?
|
| Incidence | 5 | 2013 | 1603 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 622 | 0.090 |
Why?
|
| Sphingolipids | 1 | 2013 | 337 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.090 |
Why?
|
| Health Education, Dental | 1 | 2010 | 5 | 0.090 |
Why?
|
| Computer Graphics | 2 | 2008 | 37 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1465 | 0.090 |
Why?
|
| Benzylidene Compounds | 1 | 2009 | 16 | 0.090 |
Why?
|
| Labor, Induced | 1 | 2010 | 18 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7029 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 22 | 0.090 |
Why?
|
| Confidence Intervals | 4 | 2011 | 242 | 0.090 |
Why?
|
| Shellfish | 1 | 2009 | 8 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 157 | 0.090 |
Why?
|
| Cholesterol, Dietary | 1 | 2009 | 22 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2020 | 94 | 0.090 |
Why?
|
| Amblyopia | 1 | 2010 | 43 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2012 | 419 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2009 | 219 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 77 | 0.080 |
Why?
|
| User-Computer Interface | 2 | 2011 | 230 | 0.080 |
Why?
|
| Eye | 1 | 2010 | 89 | 0.080 |
Why?
|
| Ceramides | 1 | 2013 | 578 | 0.080 |
Why?
|
| Oral Health | 1 | 2010 | 49 | 0.080 |
Why?
|
| Glycosylation | 2 | 2020 | 185 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 70 | 0.080 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2009 | 79 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 86 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 369 | 0.080 |
Why?
|
| Cataract Extraction | 1 | 2010 | 127 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2010 | 236 | 0.080 |
Why?
|
| Faith Healing | 1 | 2008 | 3 | 0.080 |
Why?
|
| Epilepsy | 2 | 2009 | 336 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2022 | 376 | 0.080 |
Why?
|
| Caseins | 1 | 2008 | 19 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 208 | 0.080 |
Why?
|
| Religion | 1 | 2008 | 23 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2019 | 1174 | 0.080 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2010 | 152 | 0.080 |
Why?
|
| Serum Albumin, Bovine | 1 | 2008 | 43 | 0.080 |
Why?
|
| Enzymes | 1 | 2008 | 25 | 0.080 |
Why?
|
| Hepatitis B Vaccines | 1 | 2008 | 11 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 2791 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 511 | 0.080 |
Why?
|
| Gastric Acidity Determination | 1 | 2008 | 62 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 320 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Protein Folding | 1 | 2008 | 82 | 0.080 |
Why?
|
| Complex Mixtures | 1 | 2008 | 14 | 0.080 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 172 | 0.080 |
Why?
|
| Computational Biology | 1 | 2009 | 190 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2019 | 1692 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2008 | 42 | 0.080 |
Why?
|
| Cholesterol | 1 | 2009 | 331 | 0.080 |
Why?
|
| Heterografts | 2 | 2020 | 70 | 0.080 |
Why?
|
| Home Care Services | 1 | 2008 | 84 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 181 | 0.070 |
Why?
|
| Biometry | 1 | 2008 | 72 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2011 | 880 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 279 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 532 | 0.070 |
Why?
|
| Coronary Disease | 1 | 2009 | 358 | 0.070 |
Why?
|
| Rural Population | 1 | 2011 | 398 | 0.070 |
Why?
|
| Heart Bypass, Right | 1 | 2007 | 30 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 300 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 286 | 0.070 |
Why?
|
| Proton Pump Inhibitors | 1 | 2008 | 91 | 0.070 |
Why?
|
| Peptide Mapping | 1 | 2006 | 39 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 425 | 0.070 |
Why?
|
| Endocardial Cushion Defects | 1 | 2006 | 11 | 0.070 |
Why?
|
| Space-Time Clustering | 1 | 2006 | 15 | 0.070 |
Why?
|
| Registries | 3 | 2018 | 733 | 0.070 |
Why?
|
| Parents | 1 | 2009 | 312 | 0.070 |
Why?
|
| Cetuximab | 2 | 2020 | 19 | 0.070 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 432 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 123 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 49 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1083 | 0.070 |
Why?
|
| Computer Simulation | 4 | 2012 | 706 | 0.070 |
Why?
|
| Endocardium | 1 | 2006 | 101 | 0.070 |
Why?
|
| Trichloroethylene | 1 | 2006 | 41 | 0.070 |
Why?
|
| Sex Factors | 3 | 2019 | 1266 | 0.070 |
Why?
|
| Decision Making | 1 | 2009 | 410 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1447 | 0.070 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2007 | 138 | 0.070 |
Why?
|
| Cell Movement | 2 | 2019 | 630 | 0.070 |
Why?
|
| Maternal Mortality | 1 | 2005 | 16 | 0.070 |
Why?
|
| Phenotype | 2 | 2019 | 947 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 83 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 318 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 378 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2007 | 275 | 0.060 |
Why?
|
| Obstetrics | 1 | 2005 | 44 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 767 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2008 | 621 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2279 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 694 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1070 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1851 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2018 | 652 | 0.050 |
Why?
|
| Pregnancy | 4 | 2010 | 2334 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Health Behavior | 1 | 2007 | 458 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2019 | 718 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 69 | 0.050 |
Why?
|
| Cell Line | 2 | 2017 | 1752 | 0.050 |
Why?
|
| Obesity | 1 | 2010 | 1076 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 34 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1033 | 0.050 |
Why?
|
| Recurrence | 3 | 2009 | 948 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2022 | 14 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2018 | 1664 | 0.050 |
Why?
|
| Physicians | 1 | 2005 | 324 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 215 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2013 | 2007 | 0.050 |
Why?
|
| DNA Damage | 1 | 2022 | 190 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 392 | 0.050 |
Why?
|
| Monte Carlo Method | 2 | 2012 | 124 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2012 | 161 | 0.050 |
Why?
|
| Colon | 1 | 2021 | 168 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 214 | 0.050 |
Why?
|
| Markov Chains | 2 | 2012 | 133 | 0.050 |
Why?
|
| Causality | 2 | 2010 | 82 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 1242 | 0.040 |
Why?
|
| Cytosol | 1 | 2020 | 123 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 260 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 138 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2020 | 358 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1553 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 310 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 71 | 0.040 |
Why?
|
| Time | 1 | 2019 | 57 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cesarean Section | 2 | 2010 | 101 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 130 | 0.040 |
Why?
|
| Poisson Distribution | 2 | 2010 | 85 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2019 | 16 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 18 | 0.040 |
Why?
|
| L-Selectin | 1 | 2019 | 28 | 0.040 |
Why?
|
| Comorbidity | 2 | 2016 | 1426 | 0.040 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2019 | 63 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2020 | 362 | 0.040 |
Why?
|
| Respiratory Aspiration | 1 | 2019 | 13 | 0.040 |
Why?
|
| Social Isolation | 1 | 2019 | 40 | 0.040 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 627 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.040 |
Why?
|
| Viscosity | 1 | 2018 | 72 | 0.040 |
Why?
|
| Transplantation Tolerance | 1 | 2018 | 13 | 0.040 |
Why?
|
| Isoantigens | 1 | 2018 | 26 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 135 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2018 | 25 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 135 | 0.040 |
Why?
|
| Databases, Protein | 2 | 2009 | 49 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 235 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 104 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 106 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 852 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 546 | 0.040 |
Why?
|
| Structural Homology, Protein | 1 | 2017 | 16 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2019 | 238 | 0.040 |
Why?
|
| Disposable Equipment | 1 | 2017 | 12 | 0.040 |
Why?
|
| Antibodies | 1 | 2018 | 241 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2018 | 149 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2017 | 42 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 2017 | 67 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2011 | 2800 | 0.040 |
Why?
|
| Food | 1 | 2017 | 52 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 742 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2018 | 308 | 0.040 |
Why?
|
| Antioxidants | 1 | 2019 | 304 | 0.040 |
Why?
|
| Laryngoscopy | 1 | 2017 | 61 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 499 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 434 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 389 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 383 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 507 | 0.030 |
Why?
|
| Mass Screening | 2 | 2012 | 843 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 163 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 500 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 68 | 0.030 |
Why?
|
| Echocardiography | 2 | 2009 | 515 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 33 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 17 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 492 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1027 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 113 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 384 | 0.030 |
Why?
|
| Cysteine | 1 | 2014 | 112 | 0.030 |
Why?
|
| Transcriptome | 1 | 2015 | 164 | 0.030 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.030 |
Why?
|
| Cell Fusion | 1 | 2013 | 23 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 782 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1034 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Urinalysis | 1 | 2013 | 27 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2013 | 20 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 929 | 0.030 |
Why?
|
| Maryland | 1 | 2013 | 77 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 140 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 134 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 1 | 2013 | 19 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 238 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 56 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 76 | 0.030 |
Why?
|
| Oropharynx | 1 | 2012 | 20 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 280 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 911 | 0.030 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2012 | 22 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 111 | 0.030 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 11 | 0.030 |
Why?
|
| Glutathione | 1 | 2014 | 343 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 145 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 63 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 142 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2013 | 525 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2012 | 131 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 242 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 791 | 0.030 |
Why?
|
| Depression | 1 | 2019 | 943 | 0.030 |
Why?
|
| Poverty | 1 | 2012 | 219 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 172 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 274 | 0.020 |
Why?
|
| Policy | 1 | 2011 | 58 | 0.020 |
Why?
|
| Education, Distance | 1 | 2011 | 34 | 0.020 |
Why?
|
| Tobacco Use Cessation | 1 | 2011 | 44 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 256 | 0.020 |
Why?
|
| Fetal Macrosomia | 1 | 2010 | 7 | 0.020 |
Why?
|
| Topography, Medical | 1 | 2010 | 10 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.020 |
Why?
|
| Apgar Score | 1 | 2010 | 22 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 306 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2010 | 46 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 772 | 0.020 |
Why?
|
| G1 Phase | 1 | 2009 | 42 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1330 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2009 | 59 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 240 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Periodontal Diseases | 1 | 2010 | 54 | 0.020 |
Why?
|
| Amniocentesis | 1 | 2009 | 12 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 521 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2009 | 80 | 0.020 |
Why?
|
| Maternal Age | 1 | 2009 | 70 | 0.020 |
Why?
|
| Birth Weight | 1 | 2010 | 186 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2010 | 91 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2010 | 204 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 90 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 786 | 0.020 |
Why?
|
| Self Administration | 1 | 2011 | 419 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 502 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 175 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2010 | 197 | 0.020 |
Why?
|
| Cell Division | 1 | 2009 | 541 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 216 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 247 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 392 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2008 | 25 | 0.020 |
Why?
|
| New York | 1 | 2008 | 223 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 420 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 955 | 0.020 |
Why?
|
| Teaching | 1 | 2010 | 169 | 0.020 |
Why?
|
| Isotopes | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cardiology | 1 | 2009 | 140 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2008 | 30 | 0.020 |
Why?
|
| Histamine H2 Antagonists | 1 | 2008 | 45 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 1293 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 298 | 0.020 |
Why?
|
| Social Class | 1 | 2008 | 127 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 320 | 0.020 |
Why?
|
| Self Care | 1 | 2010 | 253 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2007 | 53 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 657 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 575 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2006 | 25 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 133 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 618 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2007 | 85 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 649 | 0.020 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2006 | 15 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2006 | 30 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 122 | 0.020 |
Why?
|
| California | 1 | 2006 | 99 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2006 | 42 | 0.020 |
Why?
|
| Educational Status | 1 | 2007 | 273 | 0.020 |
Why?
|
| Pregnancy, High-Risk | 1 | 2005 | 14 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2006 | 379 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 337 | 0.020 |
Why?
|
| Heart Atria | 1 | 2006 | 206 | 0.020 |
Why?
|
| Mesoderm | 1 | 2006 | 231 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.010 |
Why?
|
| Water Pollutants, Chemical | 1 | 2006 | 328 | 0.010 |
Why?
|